Back to Search
Start Over
Genomic Biomarkers Predict Response to Combined ATR Inhibition and Radiotherapy.
Genomic Biomarkers Predict Response to Combined ATR Inhibition and Radiotherapy.
- Source :
-
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Dec 16; Vol. 30 (24), pp. 5505-5507. - Publication Year :
- 2024
-
Abstract
- For decades, chemoradiosensitization with checkpoint kinase inhibitors has been proposed but largely unexplored. A recent study reports that the novel ataxia telangiectasia and Rad3-related kinase inhibitor RP-3500 synergizes with radiation to control Atm-/- tumors in vivo. RP-3500 did not radiosensitize wild-type or Brca-1-deficient tumors, highlighting the need for a genotype-tailored approach. See related article by Ng et al., p. 5643.<br /> (©2024 American Association for Cancer Research.)
- Subjects :
- Humans
Biomarkers, Tumor genetics
Neoplasms genetics
Neoplasms radiotherapy
Neoplasms drug therapy
Animals
Genomics methods
Mice
Chemoradiotherapy methods
Ataxia Telangiectasia Mutated Proteins antagonists & inhibitors
Ataxia Telangiectasia Mutated Proteins genetics
Protein Kinase Inhibitors pharmacology
Protein Kinase Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1557-3265
- Volume :
- 30
- Issue :
- 24
- Database :
- MEDLINE
- Journal :
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publication Type :
- Academic Journal
- Accession number :
- 39422899
- Full Text :
- https://doi.org/10.1158/1078-0432.CCR-24-2306